Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 8/20 | 0.46 |
| ▸ | PYGM | P11217 | 3/20 | 0.45 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.45 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29047907 | 0.72 | CDA (0.55) | CDAPYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL28612080 | 0.71 | CDA (0.52) | CDAPYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL20211428 | 0.71 | CDA (0.52) | CDAPYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL18343088 | 0.71 | PYGM (0.52) | CDAPYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL13423830 | 0.71 | CDA (0.46) | CDAPYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL26099251 | 0.70 | CDA (0.49) | CDAPYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL31685237 | 0.70 | CDA (0.43) | CDAPYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL7705298 | 0.70 | CDA (0.54) | CDAPYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL10859054 | 0.70 | CDA (0.52) | CDAPYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL15010642 | 0.68 | CDA (0.53) | CDASLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941905-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |